Determination of the Pharmacokinetics and Tissue Distribution of Methyl 3,4-Dihydroxybenzoate (MDHB) in Mice Using Liquid Chromatography-Tandem Mass Spectrometry

[1]  Huanmin Luo,et al.  Neuroprotective effects of methyl 3,4 dihydroxybenzoate in a mouse model of retinitis pigmentosa , 2017, Experimental eye research.

[2]  S. Habtemariam,et al.  Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms , 2017, Evidence-based complementary and alternative medicine : eCAM.

[3]  R. Thangavel,et al.  Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..

[4]  L. Kaczmarek,et al.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes , 2017, Neuropharmacology.

[5]  B. Aungst,et al.  Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options. , 2017, Journal of pharmaceutical sciences.

[6]  Alzheimer’s Association.  2017 Alzheimer's disease facts and figures , 2017, Alzheimer's & Dementia.

[7]  R. Upton,et al.  Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations , 2017, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  F. Ahmad,et al.  Protein aggregation and neurodegenerative diseases: From theory to therapy. , 2016, European journal of medicinal chemistry.

[9]  Yan Li,et al.  [Drug glucuronidation and disposition in brain]. , 2016, Yao xue xue bao = Acta pharmaceutica Sinica.

[10]  wei zhang,et al.  Neuroprotective Effects of Methyl 3,4-Dihydroxybenzoate against TBHP-Induced Oxidative Damage in SH-SY5Y Cells , 2016, Molecules.

[11]  K. Iqbal,et al.  Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease , 2016, Molecular Neurodegeneration.

[12]  Wei Li,et al.  Simultaneous Determination and Pharmacokinetic Study of Protocatechuic Aldehyde and Its Major Active Metabolite Protocatechuic Acid in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry. , 2016, Journal of chromatographic science.

[13]  Sheila Annie Peters,et al.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models , 2016, Clinical Pharmacokinetics.

[14]  G. Kim,et al.  The Role of Oxidative Stress in Neurodegenerative Diseases , 2015, Experimental neurobiology.

[15]  Qin Gao,et al.  Methyl 3,4-dihydroxybenzoate promote rat cortical neurons survival and neurite outgrowth through the adenosine A2a receptor/PI3K/Akt signaling pathway , 2015, Neuroreport.

[16]  S. Oh,et al.  Metabolic characterization of meso-dihydroguaiaretic acid in liver microsomes and in mice. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[17]  wei zhang,et al.  Methyl 3,4-dihydroxybenzoate extends the lifespan of Caenorhabditis elegans, partly via W06A7.4 gene , 2014, Experimental Gerontology.

[18]  F. Jiménez-Jiménez,et al.  Drug and xenobiotic biotransformation in the blood–brain barrier: a neglected issue , 2014, Front. Cell. Neurosci..

[19]  A. Chacko,et al.  Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier , 2014, Perspectives in medicinal chemistry.

[20]  Li Yan,et al.  Neuroprotective effects of methyl 3,4-dihydroxybenzoate against H₂O₂-induced apoptosis in RGC-5 cells. , 2014, Journal of pharmacological sciences.

[21]  T. Davis,et al.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? , 2014, Current pharmaceutical design.

[22]  Li Yan,et al.  Methyl 3,4‐dihydroxybenzoate protects primary cortical neurons against Aβ25–35‐induced neurotoxicity through mitochondria pathway , 2013, Journal of neuroscience research.

[23]  R. Silverman,et al.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. , 2013, Journal of medicinal chemistry.

[24]  Li Yan,et al.  Methyl 3,4-dihydroxybenzoate promotes neurite outgrowth of cortical neurons cultured in vitro , 2012, Neural regeneration research.

[25]  S. Basu,et al.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. , 2011, Journal of pharmaceutical sciences.

[26]  Huaguo Chen,et al.  [Chemical constituents and bioactivity of Kalimeris indica]. , 2010, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[27]  Z. Qin,et al.  Molecular and cellular mechanisms of excitotoxic neuronal death , 2010, Apoptosis.

[28]  Xue Qiao,et al.  HPLC method for comparative study on tissue distribution in rat after oral administration of salvianolic acid B and phenolic acids from Salvia miltiorrhiza. , 2007, Biomedical chromatography : BMC.

[29]  A. Palmer,et al.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery , 2005, NeuroRx.

[30]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[31]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[32]  Liu Chang-xiao,et al.  Guidance on Bioanalysis:Method validation and analysis of study samples(Draft) , 2011 .

[33]  Guo Xing-jie.  Determination of 3,4-dihydroxy Methyl Benzoate in Hedyotis diffusa Willd. by HPLC , 2009 .

[34]  W. Humphreys,et al.  Drug metabolism in drug design and development : basic concepts and practice , 2008 .